AZTA · Azenta, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Aug 5, 2026TL;DR. Azenta reported Q3 revenue of $161M (up 9% organically) and raised full-year FY26 organic revenue guidance to flat-to-up 1%, though management cautioned that Q4 organic revenue is still expected to decline low single digits due to tough comps, while adjusted EBITDA margin contracted 60 bps YoY to 11.4%.
- + Raised full-year FY26 organic revenue guidance to approximately flat to up 1% YoY (from prior down 2% to up 1%)
- + Recurring revenue businesses (Biorepository and C&I) drove strong Sample Management Solutions growth of 9% organically
- + Repurchased ~$50M of shares (2.3M shares) under the 2025 Repurchase Program
- − Q3 adjusted EBITDA margin contracted 60 bps YoY to 11.4%
- − Adjusted gross margin declined 140 bps YoY to 46.2%, with SMS gross margin down 750 bps on Automated Stores pressure
- − Q4 organic revenue guided to decline low single digits due to tough multi-omics comp
- − Automated Stores remained below prior year levels due to slower bookings from macro-driven budget constraints
- − Sanger sequencing continues to weigh on multi-omics margins and revenue
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AZTA
this stock
Azenta, Inc.
|
$1.50B | +4.9% | +3.6% | — | 12.3% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -28.2% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -17.4% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -8.2% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AZTA | +2.4% | +10.5% | +54.0% | +6.9% | +4.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +3.0% | +10.4% | +41.8% | +7.4% | -6.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.